I67.848 Insurance Policy Changes

ICD-10 I67.848 is officially defined as "Other cerebrovascular vasospasm and vasoconstriction." code I67.848 is referenced in 4 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code I67.848 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 1, 2026Medium impact
Cerebrovascular Angioplasty, Stenting, and Select Surgical Procedures (CPB 0276, reviewed 2026-09-10)
Aetna considers angioplasty with carotid stenting medically necessary when an FDA-approved carotid stent and an FDA-approved or cleared embolic protection device are used for symptomatic carotid stenosis of at least 50% or asymptomatic stenosis of at least 70%, with duplex ultrasound as first-line evaluation, CTA or MRA confirmation when not contraindicated, and neurological assessment before and after stenting. Carotid endarterectomy is considered medically necessary for asymptomatic stenosis greater than 70% or symptomatic stenosis greater than 50%, and endovascular repair of intracranial aneurysms using stent-assisted coiling or flow diverting stents is also considered medically necessary. Intracranial angioplasty is considered medically necessary for medically refractory symptomatic delayed cerebral ischemia (cerebral vasospasm) after aneurysmal subarachnoid hemorrhage, while carotid revascularization is considered not medically necessary for members with a disabling stroke (modified Rankin scale 3 or greater), and extracranial vertebral stenting for asymptomatic stenosis, drug-eluting stents for extracranial artery stenosis, intracranial angioplasty and stenting for atherosclerotic stenosis, emergent large artery occlusion and all other indications, and permanent common carotid embolic protection devices are considered experimental, investigational or unproven.
Aetna · Identified Aug 18, 2026Medium impact
Holter Monitors (CPB 0019, reviewed 2026-03-13)
Aetna considers Holter monitoring medically necessary for diagnostic evaluation of adult members with listed conditions, including palpitations, syncope or near syncope, unexplained dizziness, and possible or documented long QT syndrome, and for asymptomatic congenital complete atrioventricular block in pediatric patients. Holter monitoring is considered experimental, investigational, or unproven for all other indications because its effectiveness for those indications has not been established. CPT codes 93224, 93225, 93226 and 93227 are covered if the selection criteria are met.
Aetna · Identified Aug 15, 2026Medium impact
Cerebral Perfusion Studies (CPB 0663, reviewed 2026-04-14)
Aetna considers CT perfusion studies of the brain medically necessary for evaluating acute stroke (less than 24 hours), including hemorrhagic stroke, subdural hemorrhage and transient ischemic attacks, for following up cerebral ischemia or infarction, for planning therapy for cervical or intracranial arterial occlusive disease, for identifying cerebral hyperperfusion after revascularization, and for evaluating the vascular status of solid tumors when MRI is degraded by susceptibility artifact. Aetna considers MRI perfusion studies medically necessary for diagnosing and following mass lesions such as glioma, for assessing acute stroke penumbra, and for assessing the hemodynamic significance of cervical or intracranial vascular stenosis and the efficacy of revascularization. Aetna considers CT perfusion experimental, investigational or unproven for indications including confirmation of brain death, differentiation of lung cancer from benign lesions, evaluation of head trauma and evaluation of cerebral vasospasm, and considers MRI perfusion unproven for indications including evaluation of traumatic brain injury, evaluation of persistent pain and prognostication of obstructive sleep apnea.
Aetna · Identified Aug 14, 2026Medium impact
Acute Ischemic Stroke Treatments (CPB 0789, reviewed 2025-11-19)
Endovascular therapy with a retrievable stent is medically necessary for acute ischemic stroke with occlusion of the middle cerebral artery trunk or its branches, or the internal carotid artery, when salvageable tissue is shown on imaging and retrieval is performed within 12 hours after stroke onset. Intra-arterial infusion of spasmolytics such as papaverine, or calcium-channel blockers such as nicardipine, into intracranial arteries is medically necessary only for medically refractory symptomatic delayed cerebral ischemia (cerebral vasospasm) after aneurysmal subarachnoid hemorrhage, and is experimental, investigational, or unproven for all other indications. Acute stenting with concomitant tirofiban, cerebrolysin, defibrinogen therapy, erythropoietin, hypothermia, transcranial ultrasound such as the CLOTBUST-HF device, sphenopalatine ganglion stimulation, statins, and vagus nerve stimulation for myocardial atrophy after AIS are experimental, investigational, or unproven, along with several other listed therapies.

Watch I67.848

Get one email when a payer policy names I67.848, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code I67.848?

There are 4 tracked policy changes affecting code I67.848, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code I67.848?

Payers that have issued tracked updates for code I67.848 include: Aetna.

How do I get notified when code I67.848 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code I67.848. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code I67.848?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Cerebrovascular Angioplasty, Stenting, and Select Surgical Procedures (CPB 0276, reviewed 2026-09-10)

Holter Monitors (CPB 0019, reviewed 2026-03-13)

Cerebral Perfusion Studies (CPB 0663, reviewed 2026-04-14)

Acute Ischemic Stroke Treatments (CPB 0789, reviewed 2025-11-19)

What insurance policy changes affect code I67.848?

Which payers have updated policy for code I67.848?

How do I get notified when code I67.848 policy changes?

Why do payers change policies for code I67.848?